Clinical Trials Logo

Myelodysplastic Syndrome (MDS) clinical trials

View clinical trials related to Myelodysplastic Syndrome (MDS).

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03335943 Not yet recruiting - Clinical trials for Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study

MD-CHINA
Start date: December 1, 2017
Phase: Phase 4
Study type: Interventional

This Study aims to evaluate the efficacy and safety of CDA-2 in the treatment of International Prognostic Scoring System (IPSS) Lower/Intermediate-risk myelodysplastic syndrome (MDS) in Chinese patients.

NCT ID: NCT02944955 Not yet recruiting - Clinical trials for Myelodysplastic Syndrome (MDS)

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Start date: January 1, 2025
Phase: Phase 2
Study type: Interventional

This is a clinical trial to determine the safety, recommended dose level (RDL), and infection control of BLEX 404 Oral Liquid in combination with azacitidine in patients with International Prognostic Scoring System (IPSS) intermediate-1 (int-1), intermediate-2 (int-2) or high-risk myelodysplastic syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).